<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Ther</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Ther</journal-id><journal-title-group><journal-title>Diabetes Therapy</journal-title></journal-title-group><issn pub-type="ppub">1869-6953</issn><issn pub-type="epub">1869-6961</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23838842</article-id><article-id pub-id-type="pmc">3889312</article-id><article-id pub-id-type="publisher-id">31</article-id><article-id pub-id-type="doi">10.1007/s13300-013-0031-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Engel</surname><given-names>Samuel S.</given-names></name><address><email>samuel.engel@merck.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Round</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Golm</surname><given-names>Gregory T.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kaufman</surname><given-names>Keith D.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Goldstein</surname><given-names>Barry J.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Merck Sharp &#x00026; Dohme Corp., Whitehouse Station, NJ USA </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>7</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>7</month><year>2013</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2013</year></pub-date><volume>4</volume><issue>2</issue><fpage>487</fpage><lpage>487</lpage><history><date date-type="received"><day>25</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2013</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d30e89" ext-link-type="doi" xlink:href="10.1007/s13300-013-0024-0"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2013</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Diabetes Ther (2013) 4:119&#x02013;145 DOI 10.1007/s13300-013-0024-0</title><p>The author of the above-mentioned paper would like to make the following adjustments to their article.</p><p>In the Results section, under &#x02018;Predefined Laboratory Abnormality Criteria&#x02019; and the subsection &#x02018;Liver Enzymes&#x02019;, the sentence in the first paragraph &#x0201c;&#x02026;the proportion of patients whose last ALT measurement was &#x02265;3 times the ULN were 0.8% and 0.6%, respectively [between-group difference 0.0]&#x02026;.&#x0201d;, should state the ALT between-group difference as 0.2, rather than 0.0.</p><p>In Table&#x000a0;3, the difference between Sitagliptin and Non-exposed (95% CI) for Neoplasms Benign, Malignant and Unspecified should read 0.5 (0.0, 1.0), rather than 0.6 (&#x02212;0.0, 1.2).</p><p>In Table&#x000a0;5, the lower bound for Dyspepsia should read 0.1, rather than 0.0.</p><p>In Table&#x000a0;6 of the Appendix, the number of patients (<italic>N</italic>) is stated incorrectly in the second and third sections of the table. The<italic> N</italic> values in all sections should read: Sitagliptin group (<italic>N</italic>&#x000a0;=&#x000a0;7,726) and Non-exposed group (<italic>N</italic>&#x000a0;=&#x000a0;6,885).</p><p>In Table&#x000a0;7 of the Appendix, the lower bound for Dyspepsia should read 0.1, not 0.0. Also, footnote &#x02018;c&#x02019; should include &#x0201c;gastrointestinal pain&#x0201d;.</p><p>The authors thank Springer Healthcare for publishing the corrections.</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s13300-013-0024-0.</p></fn></fn-group><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></ack></back></article>